Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4
ClinicoEconomics and Outcomes Research
ISSN: 1178-6981
- View all (870)
- Volume 16, 2024 (23)
- Volume 15, 2023 (67)
- Volume 14, 2022 (61)
- Volume 13, 2021 (90)
- Volume 12, 2020 (70)
- Volume 11, 2019 (71)
- Volume 10, 2018 (77)
- Volume 9, 2017 (77)
- Volume 8, 2016 (73)
- Volume 7, 2015 (64)
- Volume 6, 2014 (53)
- Volume 5, 2013 (59)
- Volume 4, 2012 (41)
- Volume 3, 2011 (19)
- Volume 2, 2010 (16)
- Volume 1, 2009 (9)
Archive: Volume 4, 2012
Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study
Jones S, Castell C, Goday A, Smith HT, Nicolay C, Simpson A, Salaun-Martin C
ClinicoEconomics and Outcomes Research 2012, 4:383-393
Published Date: 20 December 2012
Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy
Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S
ClinicoEconomics and Outcomes Research 2012, 4:375-382
Published Date: 5 December 2012
The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package
Anothaisintawee T, Leelahavarong P, Ratanapakorn T, Teerawattananon Y
ClinicoEconomics and Outcomes Research 2012, 4:361-374
Published Date: 6 December 2012
Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
Thorlund K, Druyts E, El Khoury AC, Mills EJ
ClinicoEconomics and Outcomes Research 2012, 4:349-359
Published Date: 16 November 2012
The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model
van Herick A, Schuetz CA, Alperin P, Bullano MF, Balu S, Gandhi S
ClinicoEconomics and Outcomes Research 2012, 4:337-347
Published Date: 9 November 2012
Economic analysis of Heart and Stroke Foundation of Ontario's Hypertension Management Initiative
de Oliveira C, Wijeysundera HC, Tobe SW, Moy Lum-Kwong M, Von Sychowski S, Wang X, Tu JV, Krahn MD
ClinicoEconomics and Outcomes Research 2012, 4:323-336
Published Date: 13 November 2012
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension
Granström O, Levin LA, Henriksson M
ClinicoEconomics and Outcomes Research 2012, 4:313-322
Published Date: 1 November 2012
Impact of dry eye on work productivity
Yamada M, Mizuno Y, Shigeyasu C
ClinicoEconomics and Outcomes Research 2012, 4:307-312
Published Date: 10 October 2012
Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:299-305
Published Date: 4 October 2012
Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents
Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R
ClinicoEconomics and Outcomes Research 2012, 4:287-298
Published Date: 4 October 2012
Two-factor theory – at the intersection of health care management and patient satisfaction
Bohm J
ClinicoEconomics and Outcomes Research 2012, 4:277-285
Published Date: 4 October 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:269-275
Published Date: 14 September 2012
Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation
Colombo GL, Di Matteo S, Bruno G, Girolomoni G, Vena GA
ClinicoEconomics and Outcomes Research 2012, 4:261-268
Published Date: 13 September 2012
Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis
Rønborg SM, Svendsen UG, Micheelsen JS, Ytte L, Andreasen JN, Ehlers L
ClinicoEconomics and Outcomes Research 2012, 4:253-260
Published Date: 11 September 2012
Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?
Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Foglia E, Carenzi L, Croce D
ClinicoEconomics and Outcomes Research 2012, 4:245-252
Published Date: 5 September 2012
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:237-243
Published Date: 3 September 2012
Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T
ClinicoEconomics and Outcomes Research 2012, 4:227-235
Published Date: 23 August 2012
Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era
Catay E, Castel del Cid C, Narváez L, Velozo EJ, Rosa JE, Catoggio LJ, Soriano ER
ClinicoEconomics and Outcomes Research 2012, 4:219-225
Published Date: 23 August 2012
Burden of Crohn’s disease: economics and quality of life aspects in Italy
Benedini V, Caporaso N, Corazza GR, Rossi Z, Fornaciari G, Cottone M, Frosini G, Caruggi M, Ottolini C, Colombo GL
ClinicoEconomics and Outcomes Research 2012, 4:209-218
Published Date: 24 July 2012
Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
Chien C-R, Shih Y-C,
ClinicoEconomics and Outcomes Research 2012, 4:201-208
Published Date: 25 July 2012
New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom
Gazzard B, Moecklinghoff C, Hill A
ClinicoEconomics and Outcomes Research 2012, 4:193-200
Published Date: 12 July 2012
Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece
Fragoulakis V, Kourlaba G, Tarlatzis B, Mastrominas M, Maniadakis N
ClinicoEconomics and Outcomes Research 2012, 4:185-192
Published Date: 12 July 2012
State of health economic evaluation research in Saudi Arabia: a review
Al-Aqeel SA
ClinicoEconomics and Outcomes Research 2012, 4:177-184
Published Date: 5 July 2012
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery
Hackshaw MD, Krishna A, Mauro DJ
ClinicoEconomics and Outcomes Research 2012, 4:169-176
Published Date: 18 June 2012
Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain
De Salas-Cansado M, Olivares JM, Álvarez E, Carrasco JL, Barrueta A, Rejas J
ClinicoEconomics and Outcomes Research 2012, 4:157-168
Published Date: 13 June 2012
Techniques for estimating health care costs with censored data: an overview for the health services researcher
Wijeysundera HC, Wang X, Tomlinson G, Ko DT, Krahn MD
ClinicoEconomics and Outcomes Research 2012, 4:145-155
Published Date: 1 June 2012
Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
Fragoulakis V, Kourlaba G, Maniadakis N
ClinicoEconomics and Outcomes Research 2012, 4:135-143
Published Date: 29 May 2012
Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
Fragoulakis V, Kourlaba G, Goumenos D, Konstantoulakis M, Maniadakis N
ClinicoEconomics and Outcomes Research 2012, 4:127-134
Published Date: 4 May 2012
Forecast model for the evaluation of economic resources employed in the health care of patients with HIV infection
Sacchi P, Patruno SFA, Bruno R, Cima SMB, Previtali P, Franchini A, Nicolini L, Rognoni C, Sacchi L, Bellazzi R, Filice G
ClinicoEconomics and Outcomes Research 2012, 4:117-126
Published Date: 11 May 2012
Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model
Rautenberg TA, Zerwes U, Foerster D, Aultman R
ClinicoEconomics and Outcomes Research 2012, 4:109-116
Published Date: 20 April 2012
The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
Pineo GF, Lin J, Annemans L
ClinicoEconomics and Outcomes Research 2012, 4:99-107
Published Date: 23 April 2012
Impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada: a Markov model simulation
Mortaz S, Wessman C, Duncan R, Gray R, Badawi A
ClinicoEconomics and Outcomes Research 2012, 4:91-97
Published Date: 10 April 2012
Costs and clinical consequences of suboptimal atrial fibrillation management
Singh SN
ClinicoEconomics and Outcomes Research 2012, 4:79-90
Published Date: 26 March 2012
Cost considerations in the management of atrial fibrillation – impact of dronedarone
Khaykin Y, Shamiss Y
ClinicoEconomics and Outcomes Research 2012, 4:67-78
Published Date: 6 March 2012
Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City
Díaz de León-Castañeda C, Altagracia-Martínez M, Kravzov-Jinich J, Cárdenas-Elizalde MR, Moreno-Bonett C, Martínez-Núñez JM
ClinicoEconomics and Outcomes Research 2012, 4:57-65
Published Date: 7 March 2012
Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate
Vaidya V, Patel P
ClinicoEconomics and Outcomes Research 2012, 4:49-56
Published Date: 7 February 2012
Treatment profiles and costs of patients with chronic pain in the population setting
Sicras Mainar A, Navarro Artieda R, Villoria Morillo J, Esquivias Escobar A
ClinicoEconomics and Outcomes Research 2012, 4:39-47
Published Date: 26 January 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:31-37
Published Date: 26 January 2012
Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada
Tarride JE, Haq M, Taylor VH, Sharma AM, Nakhai-Pour HR, O'Reilly D, Xie F, Dolovich L, Goeree R
ClinicoEconomics and Outcomes Research 2012, 4:21-30
Published Date: 24 January 2012
Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M
ClinicoEconomics and Outcomes Research 2012, 4:13-19
Published Date: 13 January 2012
Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
Gandhi SK, Jensen MM, Fox KM, Smolen L, Olsson AG, Paulsson T
ClinicoEconomics and Outcomes Research 2012, 4:1-11
Published Date: 10 January 2012